How to Safely Stop Cialis (Tadalafil)

Why Tadalafil Has No Withdrawal Syndrome

Tadalafil works by selectively inhibiting phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle 1. Unlike benzodiazepines or opioids, PDE5 inhibitors do not bind neuronal receptors, do not trigger receptor up-regulation, and do not alter neurotransmitter reuptake. The FDA-approved prescribing information for tadalafil lists no withdrawal reactions or discontinuation syndrome 2.

How PDE5 Inhibition Differs From Dependence-Forming Drugs

Dependence requires neuroadaptation. Tadalafil's target, the PDE5 enzyme, does not undergo compensatory upregulation after chronic exposure in human penile tissue studies 3. A 2005 analysis of long-term tadalafil use over two years found no evidence of tachyphylaxis (diminishing response) or rebound worsening of erectile function after cessation 4. Patients who stopped tadalafil in that trial returned to their baseline International Index of Erectile Function (IIEF) scores. They did not drop below baseline.

The 17.5-Hour Half-Life Advantage

Tadalafil's elimination half-life of 17.5 hours is roughly four times longer than sildenafil's 5. This pharmacokinetic profile means plasma concentrations decline slowly after the last dose, creating a built-in taper effect. Full clearance (five half-lives) takes approximately 3.5 days, so residual PDE5 inhibition persists well beyond the last pill 2.

Stopping Daily Tadalafil for Erectile Dysfunction

For men taking 2.5 mg or 5 mg tadalafil daily for ED, discontinuation is medically straightforward. The drug can be stopped on any given day. No dose reduction schedule is necessary. But the clinical picture requires more thought than simply discarding the bottle.

What Happens After the Last Dose

Erectile dysfunction itself does not resolve because the medication managed it. Within two to four days of the final dose, most men will notice that spontaneous and on-demand erectile response returns to its pre-treatment state 4. A 12-week randomized placebo-controlled trial by Porst et al. (N=348) confirmed that IIEF-EF domain scores returned to placebo-range levels once daily tadalafil 5 mg was withdrawn 6.

Assessing Whether Stopping Is Appropriate

Before discontinuation, clinicians typically reassess the original indication. The AUA/SMSNA 2018 guideline on ED recommends ongoing treatment when the underlying cause persists, such as diabetes-related endothelial dysfunction or post-prostatectomy neuropraxia 7. In cases where ED was situational (performance anxiety, medication-induced, or related to a now-resolved medical condition), stopping is reasonable. A serum testosterone level check may also be useful, since hypogonadism might have been partially masked by PDE5 inhibitor use 8.

A Practical Three-Step Check Before Discontinuing

Step 1: Confirm the reason for stopping (side effects, cost, preference, resolved etiology). Step 2: Verify cardiovascular and metabolic status. If the patient developed new risk factors during treatment (e.g., diabetes, hypertension), ED may now be worse at baseline than it was when tadalafil was started 9. Step 3: Establish a follow-up plan. The AUA recommends re-evaluation four to six weeks after any ED treatment change 7.

Stopping Daily Tadalafil for BPH (Benign Prostatic Hyperplasia)

Tadalafil 5 mg daily is the only PDE5 inhibitor FDA-approved for lower urinary tract symptoms (LUTS) secondary to BPH 2. Stopping in this population warrants closer attention than stopping for ED alone.

Symptom Return Is Predictable

The key 12-week trial by Roehrborn et al. (N=1,058) showed that tadalafil 5 mg reduced International Prostate Symptom Score (IPSS) by 4.9 points versus 2.3 for placebo 10. After discontinuation in open-label extensions, LUTS symptoms generally returned to pre-treatment severity within one to two weeks 11. No rebound worsening beyond baseline was documented.

When BPH Patients Should Not Stop Abruptly

Men on combination therapy (tadalafil plus an alpha-blocker such as tamsulosin) should not stop tadalafil without prescriber guidance. The combination addresses two separate mechanisms: smooth muscle relaxation via PDE5 inhibition and alpha-1 adrenergic blockade 12. Withdrawing one agent may unmask symptoms the other cannot fully control. The 2021 EAU guidelines recommend discussing the anticipated symptom trajectory before any medication change in LUTS management 13.

Monitoring After BPH Discontinuation

A post-void residual measurement and uroflowmetry four to six weeks after stopping can objectively quantify whether obstruction has worsened. The AUA BPH guideline suggests re-evaluation within one to three months of any medical therapy change 14.

Stopping On-Demand Tadalafil (10 mg or 20 mg)

On-demand dosing requires no discontinuation protocol because the drug is taken only as needed. There is no chronic steady-state plasma level. Patients simply stop taking it. The original Brock et al. Trial (N=1,112) that established on-demand tadalafil efficacy did not report any discontinuation effects at study end 1.

Switching From Daily to On-Demand

Some patients prefer to switch rather than stop entirely. This is clinically common when men on daily 5 mg feel the frequency is unnecessary. The transition is simple: stop daily dosing, wait 48 hours for steady-state to clear, then begin using 10 mg as needed at least 30 minutes before anticipated sexual activity 5. No adverse events from the switch have been reported in clinical literature 15.

Potential Side Effects That Resolve After Stopping

Side effects are a common reason for discontinuation. In pooled clinical trial data submitted to the FDA, the most frequent adverse events with daily tadalafil 5 mg were headache (3.8%), dyspepsia (3.1%), nasopharyngitis (2.9%), back pain (2.3%), and myalgia (1.6%) 2. All of these resolve after the drug is cleared from the body, typically within three to four days.

Rare But Notable Events

Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported in postmarketing surveillance with all PDE5 inhibitors, though a causal relationship remains unconfirmed 16. The FDA's 2007 label update required a warning but did not establish causation 17. If a patient experienced vision changes while on tadalafil, stopping the drug is mandatory, and the event should be reported to the FDA MedWatch system. No recurrence from prior exposure has been documented after cessation.

Hearing Changes

Sudden sensorineural hearing loss (SSHL) has also been reported with PDE5 inhibitors 18. FDA labeling advises immediate discontinuation if hearing loss occurs 2. These cases are exceedingly rare, and hearing typically recovers partially or fully after stopping the medication.

Drug Interaction Reasons for Stopping

Tadalafil is contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe hypotension 2. If a patient develops a cardiovascular condition requiring nitrate therapy, tadalafil must be stopped immediately. The ACC/AHA guidelines specify a minimum 48-hour washout before nitrate administration after the last tadalafil dose, reflecting the drug's longer half-life compared with sildenafil's 24-hour washout 19.

CYP3A4 Inhibitor Interactions

Potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase tadalafil AUC by 312% 2. If a patient begins a potent CYP3A4 inhibitor for another condition, stopping tadalafil or reducing the dose to 2.5 mg with no more than one dose per 72 hours is recommended per the FDA label 20.

Alpha-Blocker Caution

For patients on alpha-blockers (doxazosin, terazosin), simultaneous PDE5 inhibition can cause additive hypotension. The FDA label recommends hemodynamic stability on alpha-blocker therapy before adding tadalafil 2. If dizziness or orthostatic symptoms emerge, stopping tadalafil is the first intervention.

Psychological Considerations

Some men experience anxiety about stopping tadalafil because they equate medication cessation with loss of sexual function. A 2011 study published in the Journal of Sexual Medicine found that 22% of men using PDE5 inhibitors reported psychological dependence, defined as perceived inability to achieve erections without the drug, despite having adequate vascular function 21. This is not pharmacological dependence. It is performance anxiety.

Cognitive-Behavioral Strategies

Brief cognitive-behavioral counseling addressing performance anxiety has demonstrated efficacy in men discontinuing PDE5 inhibitors. A randomized trial by Banner and Anderson (N=60) showed that four sessions of psychosexual therapy improved IIEF scores by 4.2 points versus a control group during PDE5 inhibitor withdrawal 22. Gradual confidence-building through partner-assisted exercises may also be beneficial.

Special Populations

Post-Prostatectomy Patients

Men using daily tadalafil for penile rehabilitation after radical prostatectomy should not stop without urological guidance. The REACTT trial (N=423) showed that daily tadalafil 5 mg for nine months post-prostatectomy improved erectile function recovery at 12 months compared with on-demand or placebo 23. Premature discontinuation could compromise rehabilitation outcomes.

Pulmonary Arterial Hypertension

Tadalafil at 40 mg daily is also FDA-approved for pulmonary arterial hypertension (PAH) under the brand name Adcirca 24. Abruptly stopping PAH treatment can cause clinical deterioration, right heart failure, and hemodynamic collapse. PAH patients must never stop tadalafil without specialist supervision. The 2022 ESC/ERS pulmonary hypertension guidelines classify sudden PDE5 inhibitor withdrawal in PAH as a clinical emergency 25.

Renal and Hepatic Impairment

The FDA label recommends dose adjustment for creatinine clearance <30 mL/min (maximum 5 mg daily) and avoidance above 10 mg in Child-Pugh Class B hepatic impairment 2. When stopping in these populations, the extended elimination half-life (up to 26 hours in moderate renal impairment) means residual drug effects persist longer. No special taper is needed, but clinicians should note the prolonged washout window before starting contraindicated medications 5.

When to Restart After Stopping

If symptoms return after discontinuation and no contraindication exists, restarting tadalafil at the prior effective dose is appropriate. Long-term extension studies of up to four years show that efficacy is maintained upon rechallenge, with no dose escalation needed 26. The 2018 AUA guideline does not require a washout period before restarting a PDE5 inhibitor 7.

Patients restarting after a new cardiac event should undergo exercise stress testing or equivalent risk stratification per the Princeton III Consensus before resuming any PDE5 inhibitor 27.